We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-10.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.15B
AUM Growth
-$1.56B
Cap. Flow
-$673M
Cap. Flow %
-16.21%
Top 10 Hldgs %
47.21%
Holding
133
New
21
Increased
21
Reduced
31
Closed
23

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$71.4M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$45.8M
3
IMTX icon
Immatics
IMTX
+$39.5M
4
CTNM
Contineum Therapeutics
CTNM
+$25.2M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$19M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$149M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$146M
3
MDT icon
Medtronic
MDT
+$77M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$68.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$47.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Miscellaneous 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGRX
101
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$971K 0.02%
+173,365
New +$755K
VBIV
102
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$833K 0.02%
1,261,710
– –
TCMD icon
103
Tactile Systems Technology
TCMD
$510M
$748K 0.02%
62,639
-840,446
-93% -$11.3M
SYRS
104
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$602K 0.01%
116,754
– –
OMIC
105
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$599K 0.01%
70,896
– –
CMAX
106
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$342K 0.01%
122,643
– –
AXGN icon
107
Axogen
AXGN
$2.64B
$220K 0.01%
30,421
-1,523,508
-98% -$10.4M
RVMDW icon
108
Revolution Medicines Inc Warrant
RVMDW
$125M
$25.5K ﹤0.01%
250,000
– –
SRZNW
109
DELISTED
Surrozen Inc Warrant
SRZNW
$2.77K ﹤0.01%
166,666
– –
CMAXW
110
DELISTED
CareMax, Inc. Warrant
CMAXW
$846 ﹤0.01%
60,000
– –
ABBV icon
111
AbbVie
ABBV
$465B
– –
-106,500
Closed -$19.4M
AGIO icon
112
CALL
Agios Pharmaceuticals
AGIO
$1.96B
– –
-100,000
Closed -$2.92M
AMLX icon
113
CALL
Amylyx Pharmaceuticals
AMLX
$3.69B
– –
-1,679,125
Closed -$4.77M
AMLX icon
114
Amylyx Pharmaceuticals
AMLX
$3.69B
– –
-300,000
Closed -$852K
APLT
115
CALL
DELISTED
Applied Therapeutics
APLT
– –
-500,000
Closed -$3.4M
AUTL
116
Autolus Therapeutics
AUTL
$516M
– –
-4,330,745
Closed -$27.6M
COGT icon
117
Cogent Biosciences
COGT
$5.68B
– –
-883,333
Closed -$5.94M
ESTA icon
118
Establishment Labs
ESTA
$2.13B
– –
-82,299
Closed -$4.19M
IBRX icon
119
ImmunityBio
IBRX
$8.63B
– –
-1,052,887
Closed -$5.65M
IRON icon
120
PUT
Disc Medicine
IRON
$2.58B
– –
-300,000
Closed -$18.7M
KURA icon
121
Kura Oncology
KURA
$1.01B
– –
-48,200
Closed -$1.03M
MGNX icon
122
MacroGenics
MGNX
$257M
– –
-378,327
Closed -$5.57M
MLTX icon
123
MoonLake Immunotherapeutics
MLTX
$1.04B
– –
-339,012
Closed -$17M
NAMS icon
124
NewAmsterdam Pharma
NAMS
$2.53B
– –
-175,000
Closed -$4.14M
RAPT
125
DELISTED
RAPT Therapeutics
RAPT
– –
-152,934
Closed -$11M
2 3 4
5
6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Perceptive Advisors held 133 positions worth $4.15B, down 27% from $5.72B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors withdrew a net $673M in Q2 2024, closing 23 positions and reducing 31 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Contineum Therapeutics worth $27.6M.

  • Perceptive Advisors's largest Q2 2024 buy was Contineum Therapeutics: 1,566,668 shares worth $27.6M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q2 2024, an estimated $71.4M increase.
  • Perceptive Advisors's biggest Q2 2024 reduction was Medtronic, cutting an estimated $77M.
  • Perceptive Advisors fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $149M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $4.15B portfolio in Q2 2024.
  • Perceptive Advisors opened 21 new positions and closed 23 in Q2 2024.
  • Perceptive Advisors's portfolio value fell 27% quarter-over-quarter to $4.15B.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.